Statement of Changes in Beneficial Ownership (4)
January 04 2019 - 4:06PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Spencer David M.
|
2. Issuer Name
and
Ticker or Trading Symbol
BELLICUM PHARMACEUTICALS, INC
[
BLCM
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
Chief Technology Officer
|
(Last)
(First)
(Middle)
C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/2/2019
|
(Street)
HOUSTON, TX 77030
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
1/2/2019
|
|
M
|
|
2500
|
A
|
(1)
|
92439
|
D
|
|
Common Stock
|
1/2/2019
|
|
F
(2)
|
|
942
|
D
|
$3.33
|
91497
|
D
|
|
Common Stock
|
1/3/2019
|
|
M
|
|
1562
|
A
|
(1)
|
93059
|
D
|
|
Common Stock
|
1/3/2019
|
|
F
(3)
|
|
589
|
D
|
$3.20
|
92470
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Restricted Stock Units
|
(1)
|
1/2/2019
|
|
M
|
|
|
2500
|
(4)
|
(4)
|
Common Stock
|
2500.0
|
$0
|
7500
|
D
|
|
Restricted Stock Units
|
(1)
|
1/3/2019
|
|
M
|
|
|
1562
|
(5)
|
(5)
|
Common Stock
|
1562.0
|
$0
|
3125
|
D
|
|
Explanation of Responses:
|
(1)
|
Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of the Issuer common stock.
|
(2)
|
Represents the number of shares withheld by and surrendered to the Issuer on January 2, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 2, 2018 for 10,000 shares.
|
(3)
|
Represents the number of shares withheld by and surrendered to the Issuer on January 3, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 3, 2017 for 6,250 shares.
|
(4)
|
The RSUs vest in four equal annual installments beginning on January 2, 2019.
|
(5)
|
The RSUs vest in four equal annual installments beginning on January 3, 2018.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Spencer David M.
C/O BELLICUM PHARMACEUTICALS, INC.
2130 W. HOLCOMBE BLVD., STE. 800
HOUSTON, TX 77030
|
|
|
Chief Technology Officer
|
|
Signatures
|
/s/ Rosemary Y. Williams, Attorney-in-Fact
|
|
1/4/2019
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Apr 2023 to Apr 2024